

## Supporting Information


### Table of Contents

1. Chiral HPLC of ( <i>R</i> )-norchlorcyclizine and ( <i>R,S</i> )-norchlorcyclizine	S2
2. Retention of configuration of ( <i>R</i> )-norchlorcyclizine after reaction in DMF/Et <sub>3</sub> N, 80 °C	S3-S4
3. Chiral HPLC of ( <i>R</i> )-emoxyzine-2 and ( <i>R,S</i> )-emoxyzine-2	S5
4. <sup>1</sup> H and <sup>13</sup> C NMR spectra of emodin-PA and emoxyzine derivatives, and synthetic intermediates	S6-S32
5. Mass spectra of emodin-PA and emoxyzine derivatives	S33-S44

---


## 1. Chiral HPLC of (*R*)-norchlorcyclizine and (*R,S*)-norchlorcyclizine

1.1. HPLC of (*R*)-norchlorcyclizine, Rt = 4.8 min.



SampleName: Norchlorcyclizine R; Vial: 1:A,5; Injection: 1; Channel: PDA Spectrum; Date Acquired: 23-Mar-22 13:08:00 CET; Column Name Chiraldak IJ 3um; Acq Method Set 1596psi 2mlmn 40 5 CH3OH DEA

1.2. HPLC of (*R,S*)-norchlorcyclizine, Rt = 4.8 min (*R*) and 4.3 (S).




SampleName: Norchlorcyclizine R,S; Vial: 1:A,4; Injection: 1; Channel: PDA Spectrum; Date Acquired: 23-Mar-22 12:56:48 CET; Column Name Chiraldak IJ 3um; Acq Method Set 1596psi 2mlmn 40 5 CH3OH DEA

---


## 2. Retention of configuration of (*R*)-norchlorcyclizine after reaction in DMF/Et<sub>3</sub>N, 80 °C

### 2.1. Chiral HPLC



SampleName: Norchlorcyclizine R Et<sub>3</sub>N DMF; Vial: 1:A,6; Injection: 1; Channel: PDA Spectrum;  
Date Acquired: 23-Mar-22 13:19:14 CET; Column Name Chiraldak IJ 3um; Acq Method Set 1596psi  
2mlmn 40 5 CH<sub>3</sub>OH DEA


2.2.  $^1\text{H}$  NMR in  $\text{CDCl}_3$  (*R*)-norchlorcyclizine after heating overnight at  $80^\circ\text{C}$  in DMF/TFA, and quenching by  $\text{D}_2\text{O}$ .




---

### 3. Chiral HPLC of (*R*)-emoxyzine-2 and (*R,S*)-emoxyzine-2

#### 3.1. Chiral HPLC of (*R*)-emoxyzine-2 ( $R_t = 11.2$ min)




#### 3.2. Chiral HPLC of (*R,S*)-emoxyzine-2. $R_t = 9.6$ min (*S*, 50%), $R_t = 11.1$ min (*R*, 50%)




#### 4. $^1\text{H-NMR}$ and $^{13}\text{C-NMR}$ of emodin-PA and emoxazine derivatives, and synthesis intermediates


4.1.  $^1\text{H-NMR}$  ( $300\text{ MHz}$ ,  $\text{CDCl}_3$ ) spectrum of 1,3,8-triacetylemedin




4.2.  $^1\text{H}$  NMR (400 MHz, acetone- $d_6$ ) spectrum of 2-bromoemodin




4.3.a.  $^1\text{H}$  NMR (600 MHz, DMF- $d_7$ ) spectrum of emodin-PA-1




4.3.b.  $^{13}\text{C}$  NMR (150 MHz, DMF- $d_7$ ) spectrum of emodin-PA-1




4.4.a.  $^1\text{H}$  NMR (600 MHz,  $\text{DMSO}-d_6$ , 373 K) spectrum of emodin-PA-2




4.4.b. HMBC (600 MHz, DMSO-*d*<sub>6</sub>, 373 K) spectrum of emodin-PA-2




4.5.a.  $^1\text{H}$ NMR (600 MHz,  $\text{DMSO}-d_6$ ) spectrum of emodin-PA-3




4.5.b.  $^{13}\text{C}$  NMR (150 MHz, DMSO- $d_6$ ) spectrum of emodin-PA-3




4.6.a.  $^1\text{H}$ NMR (600 MHz,  $\text{DMSO}-d_6$ ) spectrum of emodin-PA-4




4.6.b.  $^{13}\text{C}$  NMR (150 MHz,  $\text{DMSO}-d_6$ ) spectrum of emodin-PA-4




4.7.a.  $^1\text{H}$  NMR (600 MHz,  $\text{DMSO}-d_6$ ) spectrum of emodin-PA-5




4.7.b.  $^{13}\text{C}$  NMR (150 MHz,  $\text{DMSO}-d_6$ ) spectrum of emodin-PA-5




4.8.a.  $^1\text{H}$ NMR (600 MHz,  $\text{DMSO}-d_6$ ) spectrum of emodin-PA-6




4.8.b.  $^{13}\text{C}$  NMR (150 MHz,  $\text{DMSO}-d_6$ ) spectrum of Emodin-PA-6




4.9.  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ) spectrum of emodin-link-1




4.10.  $^1\text{H}$ NMR (300 MHz,  $\text{CDCl}_3$ ) spectrum of emodin-link-2




4.11.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ) spectrum of emodin-link-3




4.12.a.  $^1\text{H}$  NMR (600 MHz, pyridine- $d_5$ ) spectrum of (*R*)-emoxyzine-1




4.12.b.  $^{13}\text{C}$  NMR (150 MHz, pyridine- $d_5$ ) spectrum of (*R*)-emoxyzine-1




4.13.a.  $^1\text{H}$  NMR (600 MHz, pyridine- $d_5$ ) spectrum of (*R*)-emoxyzine-2




4.13.b.  $^{13}\text{C}$  NMR (150 MHz, pyridine- $d_5$ ) spectrum of (*R*)-emoxyzine-2




4.14.a.  $^1\text{H}$  NMR (600 MHz, pyridine- $d_5$ ) spectrum of (*R,S*)-emoxyzine-2




4.14.b.  $^{13}\text{C}$  NMR (150 MHz, pyridine- $d_5$ ) spectrum of (*R,S*)-emoxyzine-2




4.15.a.  $^1\text{H}$  NMR (600 MHz, pyridine- $d_5$ ) spectrum of (*R*)-emoxyzine-3




4.15.b.  $^{13}\text{C}$  NMR (150 MHz, pyridine- $d_5$ ) spectrum of (*R*)-emoxazine-3



4.16.a.  $^1\text{H}$  NMR (600 MHz, pyridine- $d_5$ ) spectrum of (*R*)-emoxyzine-7




4.16.b.  $^{13}\text{C}$  NMR (150 MHz, pyridine- $d_5$ ) spectrum of (*R*)-emoxazine-7




## 5. Mass spectra of emodin-PA and emoxazine derivatives


### 5.1. MS ( $\text{ESI}^+$ ) of emodin-PA-1




5.2. MS ( $\text{ESI}^-$ ) of emodin-PA-2




5.3. MS (DCI<sup>+</sup>-CH<sub>4</sub>) of emodin-PA-3




#### 5.4. HRMS ( $\text{ESI}^+$ ) of emodin-PA-4




## 5.5. MS ( $\text{ESI}^+$ ) of emodin-PA-5




5.6. MS ( $\text{ESI}^+$ ) of emodin-PA-6




## 5.7. MS ( $\text{ESI}^+$ ) of (*R*)-emoxazine-1




5.8. MS ( $\text{ESI}^+$ ) of  $(R,S)$ -emoxyzine-1




5.9. MS ( $\text{ESI}^+$ ) of (*R*)-emoxazine-2



5.10. MS ( $\text{ESI}^+$ ) of  $(R,S)$ -emoxyzine-2



### 5.11. MS ( $\text{ESI}^+$ ) of $(R)$ -emoxyzine-3



5.12. MS ( $\text{ESI}^+$ ) of (*R*)-emoxyzine-7

